Greenwich LifeSciences Delays 10-K Filing Amid Phase III Trial Adjustments — Greenwich LifeSciences, Inc.

Event summary

Greenwich LifeSciences expects to complete its delayed Form 10-K filing by late May 2026 due to auditing adjustments related to accounts payable from its Phase III FLAMINGO-01 trial.
The company reports approximately $10.5 million in unaudited cash as of March 31, 2026, subject to change after Q1 review.
Over 1,300 patients have been screened for the FLAMINGO-01 trial, with preliminary data showing a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm.
The Phase III trial includes up to 150 global clinical sites and aims to detect a hazard ratio of 0.3 in invasive breast cancer-free survival.

The big picture

Greenwich LifeSciences' delayed 10-K filing highlights the financial complexities of managing a large-scale Phase III clinical trial, particularly with unexpected increases in patient enrollment. The preliminary efficacy data from FLAMINGO-01 suggests potential for GLSI-100 as a breakthrough immunotherapy, but the company must navigate regulatory and financial hurdles to maintain momentum in the competitive oncology space.

What we're watching

Financial Stability: Whether Greenwich LifeSciences' $10.5 million cash position will suffice until the completion of its Phase III trial and beyond.
Clinical Efficacy: How the preliminary 70-80% reduction in recurrence rates in the non-HLA-A*02 arm will translate into final study results.
Regulatory Timing: The pace at which Greenwich LifeSciences can resolve auditing discrepancies and file its Form 10-K without further delays.